Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 4, 2011, Pages 320-324

  Piso, Rein Jan ^a   Rothen, Madeleine ^a   Rothen, Jean Pierre ^b   Stahl, Matthias ^a  

^a Kantonsspital ^*  (Switzerland)

^b Medical Laboratories Olten   (Switzerland)

Author keywords

antiretroviral treatment; bone turnover markers; osteoporosis; tenofovir

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTIRETROVIRUS AGENT; DEOXYPYRIDINOLINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PYRIDINOLINE; TENOFOVIR;

ADULT; ARTICLE; BONE TURNOVER; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; SHORT COURSE THERAPY; SWITZERLAND;

ALKALINE PHOSPHATASE; AMINO ACIDS; ANTI-HIV AGENTS; BONE AND BONES; HIV INFECTIONS; HUMANS; OSTEOPOROSIS;

EID: 79952370182     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820cf010     Document Type: Article

References (21)

1. Vergidis PI, Falagas ME, Hamer DH. Meta-analytical studies on the epidemiology, prevention, and treatment of human immunodeficiency virus infection. Infect Dis Clin North Am. 2009;23:295-308.
2. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007; 146:87-95. (Pubitemid 351640011)
3. Paccou J, Viget N, Legrout-Gerot I, et al. Bone loss in patients with HIV infection. Joint Bone Spine. 2009;76:637-641.
4. Post TM, Cremers SC, Kerbusch T, et al. Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin Pharmacokinet. 2010;49:89-118.
5. Dao C, Young B, Buchacz K, et al; the Outpatients Study Investigators. Higher and increasing rates of FRacture among HIV-infected persons in the HIVoutpatient study compared to the general US population, 1994 to 2008. 17th conference on retroviruses and opportunistic infections (CROI).
6. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51:554-561.
7. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999;84:145-150. (Pubitemid 29036693)
8. Libois A, Clumeck N, Kabeya K, et al. Risk factors of osteopenia in HIVinfected women: no role of antiretroviral therapy. Maturitas. 2010;65: 51-54.
9. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23:817-824.
10. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711-e718. (Pubitemid 46089998)
11. Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV cohort study. Antivir Ther. 2008;13:1077-1082.
12. Garnero P. Bone markers in osteoporosis. Curr Osteoporos Rep. 2009;7: 84-90.
13. Knott L, Bailey AJ. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone. 1998;22:181-187. (Pubitemid 28127472)
14. Robbins JA, Schott AM, Garnero P, et al. Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos Int. 2005;16: 149-154. (Pubitemid 40193201)
15. Kraenzlin ME, Kraenzlin CA, Meier C, et al. Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases. Clin Chem. 2008;54:1546-1553.
16. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22:395-402.
17. Anastos K, Lu D, Shi O, et al. The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther. 2007;12:1049-1058. (Pubitemid 350114985)
18. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir- emtricitabine in HIV- infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963-972.
19. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519-1529.
20. McComsey G, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. 17th conference on retroviruses and opportunistic infections (CROI).
21. Mueller NJ, Fux CA, Ledergerber B, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24: 1127-1134.